FDA Foreign Inspections To Double In 2010, Led By Human Drugs And Food
This article was originally published in The Tan Sheet
Executive Summary
FDA will shoot to double its inspections of foreign facilities in fiscal 2010 to more than 2,000
You may also be interested in...
FDA Assessing Capability To Boost Surveillance Of Indian, Chinese OTC Firms
FDA is gathering information that targets tightening regulation of Indian and Chinese OTC, nutritional and traditional medicine manufacturers that use a registration loophole to export products to the U.S. under less stringent oversight.
U.S. FDA Assessing Capability To Amplify Surveillance Of Indian, Chinese OTC Manufacturers - PharmAsia Summit
The agency is gathering information to sharpen its risk-assessment approach and determine inspection priorities for nutraceuticals and traditional medicine manufacturers that use a registration loophole to export products to the U.S. under less-stringent oversight.
Regulatory Due Diligence Could Offset Foreign Manufacturing Cost-Savings
Companies that seek to save costs by manufacturing products outside the U.S. might in some cases pay a price to come into regulatory compliance for the U.S. market, FDA executives caution